{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T18:49:31Z","timestamp":1789411771041,"version":"build-2803163510"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.clinthera.2025.03.002","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T02:40:44Z","timestamp":1743043244000},"page":"405-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ethambutol Optic Neuropathy Surveillance: Variations in Real-World Screening Practices and Associated Factors in a Nationwide Cohort Study"],"prefix":"10.1016","volume":"47","author":[{"given":"Jiyeong","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4545-8344","authenticated-orcid":false,"given":"Seong Joon","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2025.03.002_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijid.2024.107325","article-title":"Insights from the 2024 WHO Global Tuberculosis Report - more comprehensive action, innovation, and investments required for achieving WHO End TB goals","volume":"150","author":"Goletti","year":"2025","journal-title":"Int J Infect Dis."},{"key":"10.1016\/j.clinthera.2025.03.002_bib0002","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/ICU.0000000000000416","article-title":"Ethambutol optic neuropathy","volume":"28","author":"Chamberlain","year":"2017","journal-title":"Curr Opin Ophthalmol"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0003","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s41433-023-02643-4","article-title":"Ethambutol and visual assessment in England: current practice and recommendations","volume":"38","author":"MacVinish","year":"2024","journal-title":"Eye (Lond)."},{"key":"10.1016\/j.clinthera.2025.03.002_bib0004","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1136\/bjophthalmol-2012-301870","article-title":"Ethambutol-induced optic neuropathy: a nationwide population-based study from Taiwan","volume":"96","author":"Chen","year":"2012","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0005","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1097\/WNO.0b013e31818e3c6b","article-title":"Incidence and clinical features of ethambutol-induced optic neuropathy in Korea","volume":"28","author":"Lee","year":"2008","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0006","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.kjms.2015.05.004","article-title":"Incidence and prognostic factor of ethambutol-related optic neuropathy: 10-year experience in southern Taiwan","volume":"31","author":"Chen","year":"2015","journal-title":"Kaohsiung J Med Sci"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0007","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5588\/ijtld.11.0766","article-title":"Incidence of ethambutol-related visual impairment during treatment of active tuberculosis","volume":"17","author":"Ezer","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0008","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.4103\/ijo.IJO_3746_20","article-title":"Ethambutol toxicity: expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy","volume":"69","author":"Saxena","year":"2021","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0009","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1461111","article-title":"Nationwide usage of ethambutol and incidence and screening practices of optic neuropathy","volume":"15","author":"Kim","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1167\/tvst.9.11.25","article-title":"Repeatability and reproducibility of axial and lateral measurements on handheld optical coherence tomography systems compared with tabletop system","volume":"9","author":"Chen","year":"2020","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0011","doi-asserted-by":"crossref","first-page":"11270","DOI":"10.1038\/s41598-024-62041-y","article-title":"Screening practices and risk assessment for maculopathy in pentosan polysulfate users across different exposure levels","volume":"14","author":"Kwon","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0012","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.oret.2023.10.005","article-title":"Nationwide usage of pentosan polysulfate and practice patterns of pentosan polysulfate maculopathy screening in South Korea","volume":"8","author":"Kim","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0013","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41598-024-51667-7","article-title":"Demographic and clinical characteristics associated with screening practices for hydroxychloroquine retinopathy","volume":"14","author":"Kim","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0014","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.14816","article-title":"Practice patterns of screening for hydroxychloroquine retinopathy in South Korea","volume":"6","author":"Kim","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0015","doi-asserted-by":"crossref","first-page":"729","DOI":"10.4103\/ijo.IJO_1920_22","article-title":"Ethambutol optic neuropathy in the extended anti-tubercular therapy regime: a systematic review","volume":"71","author":"Sabhapandit","year":"2023","journal-title":"Indian J Ophthalmol"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/toxics12080549","article-title":"Risk factors of optic neuropathy in Ethambutol users: interaction with isoniazid and other associated conditions of toxic optic neuropathy","volume":"12","author":"Kim","year":"2024","journal-title":"Toxics"},{"key":"10.1016\/j.clinthera.2025.03.002_bib0017","doi-asserted-by":"crossref","first-page":"261","DOI":"10.5588\/ijtld.15.0275","article-title":"Incidence of toxic optic neuropathy with low-dose ethambutol","volume":"20","author":"Yang","year":"2016","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182500075X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929182500075X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,5]],"date-time":"2025-05-05T13:37:42Z","timestamp":1746452262000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929182500075X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S014929182500075X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.03.002","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ethambutol Optic Neuropathy Surveillance: Variations in Real-World Screening Practices and Associated Factors in a Nationwide Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2025.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}